LA JOLLA PHARMACEUTICAL CO·4

Feb 19, 4:48 PM ET

Wellinghoff Darryl 4

4 · LA JOLLA PHARMACEUTICAL CO · Filed Feb 19, 2020

Insider Transaction Report

Form 4
Period: 2020-02-14
Wellinghoff Darryl
Chief Commercial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-02-14+229229 total
    Exercise: $8.40Exp: 2030-02-14Common Stock (229 underlying)
  • Award

    Common Stock

    2020-02-14$7.14/sh+229$1,6358,244 total
Footnotes (2)
  • [F1]These shares were acquired on 02/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  • [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.

Documents

1 file
  • 4
    wf-form4_158214889263392.xmlPrimary

    FORM 4